[go: up one dir, main page]

AR036099A1 - Derivados 6-(aril-amido o aril-amidometil)-naftalen-2-iloxi-acidogenos, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de un medicamento como inhibidores del tipo-1 inhibidor activador de plasminogeno (pai-1) - Google Patents

Derivados 6-(aril-amido o aril-amidometil)-naftalen-2-iloxi-acidogenos, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de un medicamento como inhibidores del tipo-1 inhibidor activador de plasminogeno (pai-1)

Info

Publication number
AR036099A1
AR036099A1 ARP020102313A ARP020102313A AR036099A1 AR 036099 A1 AR036099 A1 AR 036099A1 AR P020102313 A ARP020102313 A AR P020102313A AR P020102313 A ARP020102313 A AR P020102313A AR 036099 A1 AR036099 A1 AR 036099A1
Authority
AR
Argentina
Prior art keywords
phenyl
derivatives
alkyl
aril
halogen
Prior art date
Application number
ARP020102313A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR036099A1 publication Critical patent/AR036099A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/68—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/73—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/48—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Derivados 6-(aril-amido o arilamidometil)-naftalen-2-iloxi acidógenos, que comprendenn un compuesto de fórmula (1), en la cual: Ar es fenilo, naftilo, furanilo, benzofuranilo, indolilo, pirazolilo, oxazolilo, flúorenilo, fenilcicloalcano donde el cicloalcano puede ser ciclopropilo, ciclobutilo, ciclopentilo o ciclohexilo, y Ar puede estar opcionalmente sustituido con desde 1 a 3 grupos seleccionados entre alquilo C1-6, alcoxi C1-6, hidroxi, fenil-(CH2)0-6-, fenil-(CH2)0-6-O-, cicloalquilo C3-6, -(CH2)-cicloalquilo C3-6, halógeno, perflúoralquilo C1-3 y perflúoralcoxi C1-3, donde el fenilo puede estar sustituido con 1 a 3 grupos seleccionados entre alquilo C1-6, alcoxi C1-6, fenilo, halógeno, triflúormetilo o triflúormetoxi; R1 es hidrógeno, alquilo C1-6, o fenil-(CH2)1-6-, donde el fenilo puede estar sustituido con alquilo C1-6, alcoxi C1-6, halógeno, triflúormetilo o triflúormetoxi;R2 y R3 son independientemente hidrógeno, alquilo C1-6, fenil-(CH2)0-3-, halógeno y perflúoralquilo C1-3, donde el fenilo puede estar sustituido con alquilo C1-6, alcoxi C1-6, halógeno, triflúormetilo o triflúormetoxi; R4 es -CHR5CO2H ó -CH2-tetrazol, donde R5 es hidrógeno o bencilo; y n = 0 ó 1; o una forma de éster o sal farmacéuticamente aceptable del mismo, una composición farmacéutica y el uso de dichos derivados para la manufactura de un medicamento para tratamiento y prevención de un estado o evento pro-trombótico o trombótico y enfermedades de arterias coronarias o cerebrovascular.
ARP020102313A 2001-06-20 2002-06-20 Derivados 6-(aril-amido o aril-amidometil)-naftalen-2-iloxi-acidogenos, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de un medicamento como inhibidores del tipo-1 inhibidor activador de plasminogeno (pai-1) AR036099A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29965201P 2001-06-20 2001-06-20
US30865601P 2001-07-30 2001-07-30

Publications (1)

Publication Number Publication Date
AR036099A1 true AR036099A1 (es) 2004-08-11

Family

ID=26971330

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020102313A AR036099A1 (es) 2001-06-20 2002-06-20 Derivados 6-(aril-amido o aril-amidometil)-naftalen-2-iloxi-acidogenos, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de un medicamento como inhibidores del tipo-1 inhibidor activador de plasminogeno (pai-1)

Country Status (12)

Country Link
US (1) US6589970B2 (es)
EP (1) EP1397341B1 (es)
JP (1) JP4394949B2 (es)
CN (1) CN100467443C (es)
AR (1) AR036099A1 (es)
AT (1) ATE403643T1 (es)
BR (1) BR0210468A (es)
CA (1) CA2450174A1 (es)
DE (1) DE60228079D1 (es)
MX (1) MXPA03011409A (es)
TW (1) TW591020B (es)
WO (1) WO2003000649A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291639B2 (en) * 2001-06-20 2007-11-06 Wyeth Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7553867B2 (en) 2002-09-06 2009-06-30 Takeda Pharmaceutical Company Limited Furan or thiophene derivative and medicinal use thereof
EP2239012A3 (en) * 2003-04-11 2011-06-15 High Point Pharmaceuticals, LLC Substituted amide derivatives and pharmaceutical uses thereof
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7534894B2 (en) * 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
EP1723132A1 (en) * 2004-02-12 2006-11-22 Asterand Uk Limited Ep2 receptor agonists
WO2006023865A1 (en) 2004-08-23 2006-03-02 Wyeth Oxazolo-naphthyl acids as plaminogen activator inhibtor type-1 (pai-1) modulators useful in the treatment of thrombosis and cardiovascular diseases
WO2006023866A2 (en) 2004-08-23 2006-03-02 Wyeth Thiazolo-naphthyl acids as inhibitors of plasminogen activator inhibitor-1
DE102004051277A1 (de) 2004-10-21 2006-04-27 Merck Patent Gmbh Heterocyclische Carbonylverbindungen
WO2006055435A1 (en) * 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
WO2006055462A1 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7214704B2 (en) * 2004-11-15 2007-05-08 Bristol-Myers Squibb Company 2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7365061B2 (en) * 2004-11-15 2008-04-29 Bristol-Myers Squibb Company 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
MX2007008952A (es) 2005-01-27 2007-09-18 Wyeth Corp Procesos y compuestos para la preparacion de derivados de naftilindol sustituidos.
KR101394245B1 (ko) 2005-12-30 2014-05-14 에스케이바이오팜 주식회사 아이속사졸 유도체 및 이의 용도
MX2008011015A (es) * 2006-02-27 2008-11-14 Wyeth Corp Inhibidores de pai-1 para tratamiento de afecciones musculares.
JP5374840B2 (ja) 2006-07-20 2013-12-25 Ｊｎｃ株式会社 カルシウム結合発光蛋白質、それをコードする遺伝子およびその用途
AU2007285371A1 (en) 2006-08-15 2008-02-21 Actelion Pharmaceuticals Ltd. Azetidine compounds as orexin receptor antagonists
AU2007307597A1 (en) * 2006-10-12 2008-04-17 Institute Of Medicinal Molecular Design. Inc. Carboxylic acid derivatives
US7884234B2 (en) * 2006-10-12 2011-02-08 Institute Of Medicinal Molecular Design, Inc. N-phenyloxamide derivatives
AU2009225747A1 (en) * 2008-03-17 2009-09-24 Allergan, Inc. S1P3 receptor inhibitors for treating inflammation
US8633245B2 (en) * 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor
JPWO2009125606A1 (ja) 2008-04-11 2011-08-04 株式会社医薬分子設計研究所 Ｐａｉ−１阻害剤
US8722731B2 (en) 2010-06-07 2014-05-13 Novomedix, Llc Furanyl compounds and the use thereof
EP2598881A4 (en) * 2010-07-29 2014-08-13 Univ Illinois METHOD FOR PREDICTING A STROKE RISK
PT2619182T (pt) 2010-09-21 2017-01-17 Eisai R&D Man Co Ltd Composição farmacêutica
CA2997549C (en) * 2015-09-04 2023-10-03 Shin Poong Pharmaceutical Co., Ltd. Compound having effect of inhibiting platelet aggregation and salt thereof, and composition for preventing or treating thrombotic diseases, containing same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07507574A (ja) * 1993-04-05 1995-08-24 藤沢薬品工業株式会社 テストステロン５α−レダクターゼ阻害剤用インドール誘導体
ES2103181B1 (es) * 1994-08-01 1998-04-01 Menarini Lab Amidas naftalenicas con accion antagonista de los leucotrienos.
GB9402807D0 (en) * 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
DE4404662C2 (de) * 1994-02-14 1997-10-23 Windmoeller & Hoelscher Abreißwalzenpaar
WO2000031045A1 (en) 1998-11-20 2000-06-02 Torii Pharmaceutical Co., Ltd. Naphthalene derivatives

Also Published As

Publication number Publication date
BR0210468A (pt) 2004-08-10
JP4394949B2 (ja) 2010-01-06
MXPA03011409A (es) 2004-06-08
US6589970B2 (en) 2003-07-08
TW591020B (en) 2004-06-11
ATE403643T1 (de) 2008-08-15
EP1397341B1 (en) 2008-08-06
DE60228079D1 (en) 2008-09-18
US20030045560A1 (en) 2003-03-06
CA2450174A1 (en) 2003-01-03
WO2003000649A1 (en) 2003-01-03
CN1543453A (zh) 2004-11-03
JP2004536091A (ja) 2004-12-02
CN100467443C (zh) 2009-03-11
EP1397341A1 (en) 2004-03-17

Similar Documents

Publication Publication Date Title
AR036099A1 (es) Derivados 6-(aril-amido o aril-amidometil)-naftalen-2-iloxi-acidogenos, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de un medicamento como inhibidores del tipo-1 inhibidor activador de plasminogeno (pai-1)
ES2426350T3 (es) Compuestos de isoindolina sustituidos en 5
PE20242113A1 (es) Compuestos de quinolina como inhibidores de kras
PE20070541A1 (es) Compuestos y composiciones que comprenden isoindol-imidas
AR066972A1 (es) Derivados azapeptidicos
CL2003002665A1 (es) COMPUESTOS DERIVADOS DE ACIDOS CARBOXILICOS, SUS SALES; PROCEDIMIENTO DE PREPARACION; COMPOSICION FARMACEUTICA, Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES DONDE ES NECESARIO UN INHIBIDORE DEL FACTOR Xa Y /O UN INHIBIDOR DE SERINA PROTEASA.
JO2787B1 (en) Alternative amide derivatives and methods of use
TNSN07145A1 (fr) Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
ECSP088765A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
ATE361287T1 (de) Neue indol-2-on derivate
JP2005532372A5 (es)
ECSP055640A (es) Composiciones de pirazol útiles como inhibidores de gsk-3
CL2004000720A1 (es) COMPUESTOS DERIVADOS DE PIRAZOLIDINA-1,2-DICARBOXILDIFENILAMIDA, INHIBIDORES DE LOS FACTORES DE COAGULACION Xa, VIIa; PROCESO DE PREPARACION; COMPUESTOS INTERMEDIARIOS; COMPOSICION FARMACEUTICA; KIT FARMACEUTICO; Y SU USO PARA TRATAR TROMBOSIS, INFAR
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
GEP20115199B (en) Phosphatidylinositol 3-kinase inhibitors and their use
CL2012001056A1 (es) Compuestos derivados de cromenona sustituidos, inhibidores de enzimas pi 3 quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion de trastornos de proliferacion celular, tales como tumores enfermedades inflamatorias y fibroticas, asma, diabetes insulinodependiente, entre otras.
AR060675A1 (es) Derivados de n-(2-tiazolil)-amida como inhibidores de gsk-3,metodo de preparacion, composiciones farmaceuticas que los contienen,y usos terapeuticos.
NZ542495A (en) 3-alkylidenehydrazino substituted heteroaryl compounds as thrombopoietin receptor activators
WO2015047973A1 (en) FACTOR XIa INHIBITORS
BRPI0410979A (pt) composto, composição farmacêutica, e, métodos para tratar uma doença em um animal mediada pela catepsina s e para tratar um paciente submetido a uma terapia
AR022220A1 (es) Derivados de la imidazo[4,5-c]-piridin-4-ona, un procedimiento para su preparacion, el empleo de los mismos para preparar un medicamento, los medicamentosa base de estos compuestos, las composiciones farmaceuticas que contienen estos compuestos y un procedimiento para preparar estas composiciones fa
UA93393C2 (uk) 1,3-діоксанкарбонові кислоти
BRPI0509074A (pt) composições farmacêuticas compreendendo agonistas do receptor da tiróide
DE602004015406D1 (de) Verwendung von 3-methoxy-pregnenolon bei der herstellung eines arzneimittels zur behandlung von neurodegenerativen erkrankungen
NO20070789L (no) Nikotinreseptoragonister for behandling av betennelsessykdommer

Legal Events

Date Code Title Description
FB Suspension of granting procedure